249 related articles for article (PubMed ID: 25020203)
21. Prophylactic Effect of Premedication with Intravenous Magnesium on Renal Dysfunction in Preoperative Cisplatin-Based Chemotherapy for Esophageal Cancer.
Kubo Y; Miyata H; Sugimura K; Shinno N; Ushigome H; Yanagimoto Y; Takahashi Y; Yamamoto K; Nishimura J; Wada H; Takahashi H; Yasui M; Omori T; Ohue M; Yano M
Oncology; 2019; 97(6):319-326. PubMed ID: 31553989
[TBL] [Abstract][Full Text] [Related]
22. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.
Crona DJ; Faso A; Nishijima TF; McGraw KA; Galsky MD; Milowsky MI
Oncologist; 2017 May; 22(5):609-619. PubMed ID: 28438887
[TBL] [Abstract][Full Text] [Related]
23. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study.
Oka T; Kimura T; Suzumura T; Yoshimoto N; Nakai T; Yamamoto N; Matsuura K; Mitsuoka S; Yoshimura N; Kudoh S; Hirata K
BMC Pharmacol Toxicol; 2014 Dec; 15():70. PubMed ID: 25472655
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of renal function using the level of neutrophil gelatinase-associated lipocalin is not predictive of nephrotoxicity associated with cisplatin-based chemotherapy.
Kos FT; Sendur MA; Aksoy S; Celik HT; Sezer S; Civelek B; Yaman S; Zengin N
Asian Pac J Cancer Prev; 2013; 14(2):1111-4. PubMed ID: 23621196
[TBL] [Abstract][Full Text] [Related]
25. Multivariate analysis of risk factors for cisplatin-induced nephrotoxicity in gynecological cancer.
Yamamoto Y; Watanabe K; Matsushita H; Tsukiyama I; Matsuura K; Wakatsuki A
J Obstet Gynaecol Res; 2017 Dec; 43(12):1880-1886. PubMed ID: 28984058
[TBL] [Abstract][Full Text] [Related]
26. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
Ikemura K; Oshima K; Enokiya T; Okamoto A; Oda H; Mizuno T; Ishinaga H; Muraki Y; Iwamoto T; Takeuchi K; Katayama N; Okuda M
Cancer Chemother Pharmacol; 2017 May; 79(5):943-949. PubMed ID: 28364288
[TBL] [Abstract][Full Text] [Related]
27. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia.
Prasaja Y; Sutandyo N; Andrajati R
Asian Pac J Cancer Prev; 2015; 16(3):1117-22. PubMed ID: 25735341
[TBL] [Abstract][Full Text] [Related]
28. The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial.
Sainamthip P; Saichaemchan S; Satirapoj B; Prasongsook N
JCO Glob Oncol; 2022 Mar; 8():e2100275. PubMed ID: 35436142
[TBL] [Abstract][Full Text] [Related]
29. Renal tolerance to cisplatin in patients 70 years and older.
Cubillo A; Cornide M; López JL; Molina R; Feliu J; Espinosa E; Zamora P; de Castro J; Ordoñez A; González Barón M
Am J Clin Oncol; 2001 Apr; 24(2):192-7. PubMed ID: 11319297
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of acute and chronic nephrotoxicity in patients received cisplatin-based chemotherapy: has anything changed over time?
Kamacı ŞÇ; Koçak G; Yeşilova A; Cihan Ş
Int Urol Nephrol; 2022 May; 54(5):1085-1090. PubMed ID: 34390437
[TBL] [Abstract][Full Text] [Related]
31. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
Merouani A; Davidson SA; Schrier RW
Am J Nephrol; 1997; 17(1):53-8. PubMed ID: 9057954
[TBL] [Abstract][Full Text] [Related]
32. Influence of magnesium and parathyroid hormone on cisplatin-induced nephrotoxicity in esophageal squamous cell carcinoma.
Konishi H; Fujiwara H; Itoh H; Shiozaki A; Arita T; Kosuga T; Morimura R; Komatsu S; Ichikawa D; Okamoto K; Otsuji E
Oncol Lett; 2018 Jan; 15(1):658-664. PubMed ID: 29391892
[TBL] [Abstract][Full Text] [Related]
33. Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC study).
Suppadungsuk S; Phitakwatchara W; Reungwetwattana T; Pathumarak A; Phakdeekitcharoen B; Kitiyakara C; Srisuwarn P; Davenport A; Nongnuch A
ESMO Open; 2022 Feb; 7(1):100351. PubMed ID: 34953401
[TBL] [Abstract][Full Text] [Related]
34. [Feasibility of short volume hydration in patients with lung cancer treated with Cisplatin-containing chemotherapy].
Ohhara Y; Isobe H; Ito K; Fuke S; Kojima T; Saito H; Nishiura Y
Gan To Kagaku Ryoho; 2015 Jan; 42(1):57-61. PubMed ID: 25596680
[TBL] [Abstract][Full Text] [Related]
35. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
[TBL] [Abstract][Full Text] [Related]
36. Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center.
Williams RP; Ferlas BW; Morales PC; Kurtzweil AJ
J Oncol Pharm Pract; 2017 Sep; 23(6):422-428. PubMed ID: 27352615
[TBL] [Abstract][Full Text] [Related]
37. Magnesium depletion enhances cisplatin-induced nephrotoxicity.
Lajer H; Kristensen M; Hansen HH; Nielsen S; Frøkiaer J; Ostergaard LF; Christensen S; Daugaard G; Jonassen TE
Cancer Chemother Pharmacol; 2005 Nov; 56(5):535-42. PubMed ID: 15947931
[TBL] [Abstract][Full Text] [Related]
38. A systematic review for prevention of cisplatin-induced nephrotoxicity using different hydration protocols and meta-analysis for magnesium hydrate supplementation.
Li J; Wu Y; Chen C; Zhang W; Yue L; Liu T
Clin Exp Nephrol; 2024 Jan; 28(1):1-12. PubMed ID: 37530867
[TBL] [Abstract][Full Text] [Related]
39. Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity.
Takagi A; Miyoshi T; Hayashi T; Koizumi H; Tsumagari K; Yokota C; Nakano T; Matsuo K; Egawa T
Sci Rep; 2024 May; 14(1):10511. PubMed ID: 38714773
[TBL] [Abstract][Full Text] [Related]
40. Risk Factors for Nephrotoxicity Associated with Cisplatin.
Almanric K; Marceau N; Cantin A; Bertin É
Can J Hosp Pharm; 2017; 70(2):99-106. PubMed ID: 28487576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
